Prolocor Receives Funds From Seed Round and NIH SBIR Grant to Develop Thrombosis-Risk Prediction Tool

August 16, 2022—Prolocor, Inc., a health care startup developing a precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa on the surface of platelets, announced the closing of an oversubscribed $3.2 million seed round. Prolocor’s precision tool is intended to guide thrombosis treatment decisions to effectively match the intensity of therapy with the risk of events in patients with acute coronary syndrome.

Prolocor also announced the receipt of a $2 million Phase II grant from the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH). Funds from this grant will be used to support the analytical validation of platelet expression of FcγRIIa as a precision tool.

With this funding, the company plans to establish a CLIA-certified laboratory and complete an ongoing prospective, observational multicenter noninterventional cohort study in 800 patients who have experienced heart attacks.

Prolocor was founded in 2020 by CEO Peter M. DiBattiste, MD, and CSO David J. Schneider, MD. The company is based in Philadelphia, Pennsylvania.

In Prolocor’s press release, Dr. Schneider commented, “The combined funding from the seed round and the NIH SBIR grant will allow us to make significant progress towards validating FcγRIIa as a precision tool for patients with cardiovascular disease.”

The financing round was led by Green Park & Golf (GPG) Ventures, with participation from Labcorp and a group of angel investors, advised the company.

Clay Heighten, Managing Partner at GPG Ventures, stated in the press release, “We are inspired by the work of Co-Founder and CSO Dr. David Schneider in advancing the understanding of thrombotic risk in coronary artery disease and are excited to participate in moving the technology from the lab to the clinic. Dr. Peter DiBattiste is eminently qualified to coordinate the clinical studies, which are expected to prove the value of the Prolocor test.”